Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
Pierre FoidartCassandre YipJean RadermacherSilvia BlacherMehdi LienardLaetitia Montero-RuizErik MaquoiElodie MontaudonSophie Château-JoubertJoëlle CollignonMichel CoibionVéronique JossaElisabetta MarangoniAgnès NoëlNor Eddine SounniGuy JerusalemPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
We defined a new association of three biomarkers (MT4-MMP/EGFR/RB) expressed together in 50% of TNBC and demonstrated its usefulness to predict the TNBC response to anti-EGFR and anti-CDK4/6 drugs used in single or combined therapy.